IntegraGen SA
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
IntegraGen SA - overview
Established
2000
Location
-, -, France
Primary Industry
Biotechnology
About
IntegraGen SA is a biotechnology company specializing in genomic testing and data analysis services, focusing on oncology and rare genetic diseases to support research and clinical applications. IntegraGen SA was founded in 2000 and is headquartered in France. The company engages in genomic testing and bioinformatics, providing valuable insights for research institutions and biopharmaceutical companies. Eric Letouzé is the founder, and Bernard Courtieu serves as the CEO.
IntegraGen has participated in 6 deals, with the most recent deal completed on June 19, 2010, when the company executed a PIPE funding round that raised EUR 2. 00 mn, bringing the total amount raised to EUR 2. 00 mn, with A Plus Finance as an investor. IntegraGen specializes in genomic testing and data analysis software tailored for researchers and clinicians in oncology and rare genetic diseases.
Their main offerings include next-generation sequencing services, custom bioinformatics, and biostatistical tools, enabling effective genomic data analysis. These services are critical for advancing molecular diagnostics and personalized medicine, particularly for clients such as academic laboratories and private research institutions in Europe and North America, where there is a rising demand for genomic solutions. In 2023, IntegraGen reported a revenue of EUR 13,570,451. 70 and an EBITDA of EUR 87,235.
60. The company's revenue model focuses on providing genomic testing and bioinformatics services on a B2B basis, primarily to research institutions and biopharmaceutical firms. Their transactions involve service contracts designed to meet client needs, including ongoing subscriptions for bioinformatics tools and project-based fees for analyses, with key offerings like Mercury for tumor genomic analysis and Galiléo for gene expression analysis contributing to their revenue stream. IntegraGen is focused on developing new products that leverage advancements in genomic technology, with plans to introduce these products in upcoming quarters.
Additionally, the company aims to expand its market presence into new geographic regions, including Asia and South America, by 2025. The recent funding from the PIPE round will support these initiatives, facilitating product development and market entry strategies.
Current Investors
Idinvest Partners, CDC Enterprises, SGAM Private Equity
Primary Industry
Biotechnology
Sub Industries
Bioinformatics, Diagnostic, Medical & Imaging Laboratories, Oncology/Cancer Treatment, Nanomaterials
Website
www.integragen.fr
Verticals
HealthTech
Company Stage
Mature
Total Amount Raised
Subscriber access only
IntegraGen SA - timeline of key events
IntegraGen SA - financials
| Fiscal Year Ended | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 5,407,674 | 6,035,595 | 5,583,987 | 6,022,000 | 6,247,000 | 6,922,000 | 8,280,000 | 8,979,591 | 11,323,959 | - | - | - |
| % Revenue Growth (YoY) | - | 11.6% | (7.5%) | 7.8% | 3.7% | 10.8% | 19.6% | 8.4% | 26.1% | - | - | - |
| EBITDA (USD) | (2,812,622) | (1,599,685) | (2,229,176) | (1,695,375) | (1,806,698) | (1,037,000) | (70,000) | (27,794) | 162,360 | - | - | - |
| Operating Income (USD) | (2,892,979) | (1,700,723) | (2,317,597) | (1,801,000) | (1,930,000) | (1,179,000) | (363,000) | (254,138) | (43,529) | - | - | - |
| Operating Margin | (53.5%) | (28.2%) | (41.5%) | (29.9%) | (30.9%) | (17.0%) | (4.4%) | (2.8%) | (0.4%) | - | - | - |
| % EBITDA Margin | (52.0%) | (26.5%) | (39.9%) | (28.2%) | (28.9%) | (15.0%) | (0.8%) | (0.3%) | 1.4% | - | - | - |
| NET Income (USD) | (2,545,619) | (1,036,226) | (1,533,806) | (1,650,000) | (862,000) | (1,140,000) | (285,000) | (375,021) | 15,407 | - | - | - |
| % Net Margin | (47.1%) | (17.2%) | (27.5%) | (27.4%) | (13.8%) | (16.5%) | (3.4%) | (4.2%) | 0.1% | - | - | - |
IntegraGen SA - employee data
IntegraGen SA - key contacts
| Name | Position | Start Date | End Date | Vcard | Bio | ||
|---|---|---|---|---|---|---|---|
| membre du conseil d'administration | BM |
BM Board Member
Want to see more?
Request a demo for full access to this profile
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.